Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 2/20 | 0.44 |
| ▸ | FGB | P02675 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663857 | 0.97 | EGFR (0.47) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6666935 | 0.96 | MAPT (0.45) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6660597 | 0.94 | MALT1 (0.51) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6665635 | 0.88 | MALT1 (0.45) | SMN1; SMN2MEN1POLBBLMKMT2A | |
| SCHEMBL6661017 | 0.87 | CAPN1 (0.42) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12658883 | 0.86 | MALT1 (0.54) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6662701 | 0.85 | CYP19A1 (0.43) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6666346 | 0.85 | MAPT (0.47) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6657720 | 0.85 | MAPT (0.47) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6662275 | 0.84 | MAPT (0.47) | EGFRMAPTMAPK1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | EGFR 1444/4885MAPT 4879/4885MAPK1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.